Dianthus Therapeutics (DNTH) financial statements
Dianthus Therapeutics reported revenue of $2M in fiscal 2025, down 15.1% a year over 2 years.
Net income was -$162M.
Free cash flow was -$129M.
The diluted share count rose 25746% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Dianthus Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | $3M | $6M | $2M |
| Research and development | $6M | $28M | $41M | $59M | $51M | $47M | $29M | $33M | $83M | $146M |
| Selling, general and admin | $3M | $8M | $19M | $24M | $28M | $28M | $7M | $18M | $25M | $34M |
| Operating income | -$9M | -$36M | -$60M | -$83M | -$79M | -$75M | -$30M | -$48M | -$102M | -$178M |
| Interest expense | $163,000 | — | — | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9M | -$35M | -$58M | -$77M | -$75M | -$71M | -$28M | -$44M | -$85M | -$162M |
| EPS (diluted) | -$65.15 | -$19.12 | -$3.13 | -$2.07 | -$1.71 | -$1.29 | -$32.57 | -$8.45 | -$2.55 | -$4.20 |
| Diluted shares | 0M | 2M | 18M | 37M | 44M | 55M | 1M | 5M | 33M | 39M |
| Operating margin | — | — | — | — | — | — | — | -1704.7% | -1633.7% | -8739.3% |
| Net margin | — | — | — | — | — | — | — | -1541.2% | -1362.8% | -7973.3% |
Balance sheet
Fiscal years, from Dianthus Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $5M | $51M | $143M | $146M | $149M | $177M | $118M | $131M | $22M | $50M |
| Receivables | — | — | — | — | — | — | $5M | $294,000 | $0 | $52,000 |
| Total current assets | — | $53M | $145M | $150M | $152M | $181M | $82M | $177M | $281M | $409M |
| Property, plant and equipment | — | $2M | $10M | $10M | $8M | $7M | $142,000 | $185,000 | $194,000 | $296,000 |
| Total assets | — | $54M | $157M | $162M | $162M | $190M | $83M | $179M | $374M | $531M |
| Total current liabilities | — | $4M | $10M | $14M | $11M | $11M | $8M | $10M | $18M | $31M |
| Total liabilities | — | $4M | $12M | $20M | $18M | $17M | $9M | $11M | $22M | $38M |
| Shareholders' equity | -$9M | -$42M | $146M | $141M | $144M | -$17M | -$44M | $169M | $352M | $493M |
| Net debt | -$5M | -$51M | -$58M | -$65M | -$58M | -$132M | -$58M | -$132M | -$23M | -$51M |
Cash flow
Fiscal years, from Dianthus Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7M | -$22M | -$42M | -$57M | -$64M | -$60M | -$29M | -$37M | -$78M | -$129M |
| Capital spending | $139,000 | $2M | $8M | $3M | $400,000 | $1M | $314,000 | $110,000 | $105,000 | $213,000 |
| Free cash flow | -$7M | -$24M | -$50M | -$60M | -$64M | -$61M | -$29M | -$37M | -$78M | -$129M |
| Stock-based compensation | $662,000 | $2M | $11M | $10M | $10M | $10M | $2M | $3M | $13M | $23M |
| Free cash flow margin | — | — | — | — | — | — | — | -1308.2% | -1255.6% | -6349.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DNTH.
Open DNTH in InvestinglyQuestions
What was Dianthus Therapeutics's revenue in 2025?
$2M in fiscal 2025, from its 10-K filing.
How much free cash flow does Dianthus Therapeutics generate?
-$129M in fiscal 2025 (operating cash flow minus capital spending).
From Dianthus Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.